Added to YB: 2024-11-22
Pitch date: 2024-11-21
SAVA [bearish]
Cassava Sciences, Inc.
+95.41%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Market Cap
$62.8M
Pitch Price
$31.36
Price Target
3.00 (+108%)
Dividend
N/A
Sector
Pharmaceuticals
Category
N/A
Show full summary:
Cassava's Valuation at Risk Amid Increasing Skepticism Around Simufilam
SAVA short: Simufilam can't work for Alzheimer's. Poor PK, short half-life, weak brain penetration. Mechanism implausible. Clinical trials show ineffectiveness (p=0.45). 98% Phase 3 AD trial failure rate. Treating symptomatic patients. $2-3 price target based on cash value.
Read full article (1 min)